Single dose combination of sulfametoxazole/trimethoprim after percutaneous endoscopic gastrostomy

ISRCTN ISRCTN18677736
DOI https://doi.org/10.1186/ISRCTN18677736
Secondary identifying numbers 2005-100 002
Submission date
13/11/2009
Registration date
04/01/2010
Last edited
04/08/2010
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Surgery
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English summary of protocol

Not provided at time of registration

Contact information

Dr John Blomberg
Scientific

Unit of Gastrointestinal Research Group (UGIR)
Karolinska Institutet
Norra Stationsgatan 67
Stockholm
17176
Sweden

Phone +46 (0)8 517 709 83
Email john.blomberg@karolinska.se

Study information

Study designSingle centre double blind randomised controlled trial
Primary study designInterventional
Secondary study designRandomised controlled trial
Study setting(s)Hospital
Study typeTreatment
Participant information sheet Not available in web format, please use the contact details below to request a patient information sheet
Scientific titleSingle dose combination of sulfametoxazole/trimethoprim after percutaneous endoscopic gastrostomy versus standard prophylaxis before percutaneous endoscopic gastrostomy: a single centre double blind randomised controlled trial
Study objectivesA single dose combination of a sulfonamide and trimethoprim (Bactrim®), in an oral solution, given in the percutaneous endoscopic gastrostomy (PEG) catheter immediately after the PEG procedure, is as good as the standard prophylaxis with Zinacef® given intravenously minutes before the PEG procedure.
Ethics approval(s)Regional ethical committee in Stockholm approved on the 2nd June 2005 (ref: 2005/505-31)
Health condition(s) or problem(s) studiedPercutaneous endoscopic gastrostomy procedure
InterventionSingle dose of 20 ml oral solution of sulfamethoxazole/trimethoprim (Bactrim®) given in the PEG-catheter immediately after PEG compared to standard treatment (single dose of 1.5 g of cefuroxime [Zinacef®] given intravenously moments before PEG).

Planned follow up once at 7 - 14 days after the PEG procedure in both study arms.
Intervention typeDrug
Pharmaceutical study type(s)
PhasePhase IV
Drug / device / biological / vaccine name(s)Sulfonamide and trimethoprim (Bactrim®), cefuroxime (Zinacef®)
Primary outcome measureParastomal infection at follow up
Secondary outcome measuresMeasured at baseline and follow up:
1. Highly sensitive C-reactive protein
2. White blood cell count
3. Body mass index (BMI)
4. Complications
Overall study start date03/06/2005
Completion date30/11/2009

Eligibility

Participant type(s)Patient
Age groupAdult
SexBoth
Target number of participants200 (100 in each arm)
Key inclusion criteria1. Aged greater than or equal to 15 years, either sex
2. Need for PEG
3. Gives oral consent to the study
4. No contraindication for PEG
Key exclusion criteria1. Ongoing antibiotic treatment
2. Allergy to study drug or standard treatment
3. Saying no to participation
4. Too sick to be able to give consent
Date of first enrolment03/06/2005
Date of final enrolment30/11/2009

Locations

Countries of recruitment

  • Sweden

Study participating centre

Unit of Gastrointestinal Research Group (UGIR)
Stockholm
17176
Sweden

Sponsor information

Karolinska Institutet (Sweden)
Research organisation

c/o Jesper Lagergren
Unit of Gastrointestinal Research Group (UGIR)
Norra Stationsgatan 67
Stockholm
17176
Sweden

Phone +46 (0)8 517 760 12
Email jesper.lagergren@ki.se
Website http://ki.se/ki/jsp/polopoly.jsp?d=130&l=sv
ROR logo "ROR" https://ror.org/056d84691

Funders

Funder type

Research organisation

Swedish Cancer Society (Sweden)
Private sector organisation / Trusts, charities, foundations (both public and private)
Alternative name(s)
Swedish Cancer Society
Location
Sweden

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planNot provided at time of registration
IPD sharing plan

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Results article results 02/07/2010 Yes No